摘要
目的:研究布地格福吸入气雾剂治疗重度慢性阻塞性肺疾病(COPD)的效果。方法:选取2021年3月—2022年3月莆田市第一医院收治的150例重度COPD患者,按系统化随机法将其分为两组,各75例。对照组予布地奈德福莫特罗吸入粉雾剂+噻托溴铵吸入粉雾剂治疗,观察组予布地格福吸入气雾剂治疗。比较两组治疗前和治疗3个月后的肺功能指标[第1秒用力呼气容积(FEV_(1))、用力肺活量(FVC)和第1秒用力呼气容积/用力肺活量(FEV_(1)/FVC%)]、运动耐量[6 min步行试验(6MWT)]、慢阻肺患者自我评估测试问卷(CAT)评分、圣乔治呼吸问卷(SGRQ)评分和治疗期间不良反应发生情况。结果:治疗3个月后,两组FEV_(1)、FVC、FEV_(1)/FVC%及6MWD均优于治疗前,CAT评分、SGRQ评分均低于治疗前,且观察组改善幅度优于对照组,差异有统计学意义(P<0.05)。治疗期间,两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:与布地奈德福莫特罗联合噻托溴铵治疗相比,布地格福吸入气雾剂治疗重度COPD患者的效果更明显,能改善患者临床症状和生活质量,促进肺功能和运动耐量的恢复。
Objective:To investigate the effect of Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol on severe chronic obstructive pulmonary disease(COPD).Method:A total of 150 patients with severe COPD who admitted to Putian First Hospital from March 2021 to March 2022 were selected as the research objects,and they were divided into two groups according to systematic randomization,75 cases in each group.The control group was treated with Budesonide and Formoterol Fumarate Powder for Inhalation+Tiotropium Bromide Powder for Inhalation,and the observation group was treated with Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol.The lung function indexes[forced expiratory volume in the first second(FEV_(1)),forced vital capacity(FVC)and forced expiratory volume in the first second/forced vital capacity(FEV_(1)/FVC%)],exercise tolerance[6-min walking test(6MWT)],COPD assessment test(CAT)and St.George's respiratory questionnaire(SGRQ)scores before and after treatment and the occurrence of adverse reactions during treatment were compared between the two groups.Result:After 3 months of treatment,the FEV_(1),FVC,FEV_(1)/FVC%and 6MWD of two groups were better than those before treatment,CAT scores and SGRQ scores were lower than those before treatment,and the improvement range of the observation group were better than those of the control group,the differences were statistically significant(P<0.05).During treatment,there was no significant difference in the incidence of adverse reactions between two groups(P>0.05).Conclusion:Compared with Budesonide Formoterol combined with Tiotropium Bromide,Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol is effective in the treatment of patients with severe COPD,it can improve the clinical symptoms and quality of life of patients,and promote the recovery of lung function and exercise tolerance.
作者
郑笑红
ZHENG Xiaohong(Putian First Hospital,Putian 351100,China)
出处
《中外医学研究》
2023年第9期13-16,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
布地格福吸入气雾剂
布地奈德福莫特罗
噻托溴铵
重度慢性阻塞性肺疾病
Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol
Budesonide Formoterol Tiotropium Bromide
Severe chronic obstructive pulmonary disease
